SAN DIEGO--(BUSINESS WIRE)--Stemson Therapeutics and Aderans Company, the parent company of Bosley® and HAIRCLUB®, today announced an agreement securing Stemson the exclusive global rights to research, develop and commercialize hair regeneration therapeutic products based on Aderans’ proprietary hair regeneration cell therapy technology.

圣地亚哥--（商业新闻短讯）--斯特姆森治疗公司（Stemson Therapeutics）和阿德兰公司（Aderans Company），Bosley®和Hairlub®的母公司，今天宣布了一项协议，确保斯特姆森拥有基于阿德兰专有毛发再生细胞治疗技术的毛发再生治疗产品的全球独家研究、开发和商业化权利。

Stemson, a leader in developing a proprietary cell therapy technology for reversing hair loss based on induced pluripotent stem cells (iPSC), gains a complementary technology through this agreement. Stemson will resume Aderans’ Phase 2 clinical stage cell therapy hair regeneration program, integrate the technology into its existing hair loss cell therapy development pipeline, and provide multiple products for patients experiencing hair loss.

斯特姆森是基于诱导多能干细胞（iPSC）开发专有细胞治疗技术以逆转脱发的领导者，通过该协议获得了一项补充技术。斯特姆森将恢复阿德兰的第二阶段临床阶段细胞疗法毛发再生计划，将该技术整合到其现有的脱发细胞疗法开发管道中，并为脱发患者提供多种产品。

Aderans’ proprietary hair regeneration platform is a cell therapy system that utilizes patient-derived hair and skin cells to durably rejuvenate shrinking hair follicles in patients with Androgenetic Alopecia by repopulating functional hair follicle cells into early-to-mid stage hair loss areas. Aderans Co., a Tokyo-based global leader in hair products and services, conducted Phase 2 clinical testing in the United States on 445 human patients to treat early-to-mid stage Androgenetic Alopecia in men and women.

Aderans专有的毛发再生平台是一种细胞治疗系统，它利用患者来源的头发和皮肤细胞，通过将功能性毛囊细胞重新填充到早期至中期脱发区域，持久地恢复雄激素性脱发患者萎缩的毛囊。总部位于东京的头发产品和服务全球领导者阿德兰公司（Aderans Co.）在美国对445名人类患者进行了第二阶段临床测试，以治疗男性和女性的早期至中期雄激素性脱发。

Initial clinical data suggest a single dose of functional hair follicle cells into the target scalp area can safely produce long lasting and durable hair growth results. Stemson intends to leverage this technology as it continues development of iPSC-derived autologous cell therapy to regenerate healthy hair follicles.

最初的临床数据表明，单剂量的功能性毛囊细胞进入目标头皮区域可以安全地产生持久和持久的毛发生长结果。斯特姆森打算利用这项技术，继续开发iPSC衍生的自体细胞疗法，以再生健康的毛囊。

Stemson has successfully created human hair follicles in humanized mice using engineered follicular units which are designed to provide an unlimited source of hair follicle replacements capable of treating a range of hair loss indications.

斯特姆森已成功使用工程卵泡单位在人源化小鼠中创建了人类毛囊，该单位旨在提供无限的毛囊替代物来源，能够治疗一系列脱发指征。

“The addition of Aderans technology and their Phase 2 clinical stage development program into the Stemson portfolio enables us to expand our pursuit of multiple cell therapy product concepts to address a broad range of hair loss indications,” said Geoff Hamilton, CEO of Stemson Therapeutics. “Aderans’ early pioneering work in cell therapy for hair loss demonstrated to the field the potential for durable long lasting hair regeneration results by restoring functional hair cells and tissue.

Stemson Therapeutics首席执行官杰夫·汉密尔顿（GeoffHamilton）表示：“将Aderans技术及其2期临床阶段开发计划加入到Stemson产品组合中，使我们能够扩大对多种细胞疗法产品概念的追求，以解决广泛的脱发指征。”。Aderans在脱发细胞治疗方面的早期开创性工作向该领域证明了通过恢复功能性毛细胞和组织来实现持久持久的头发再生的潜力。

We are excited to combine their work with our cell and tissue engineering capabilities in the hair regeneration field to create truly breakthrough products for hair loss patients. The synergies between the Aderans technology and Stemson’s in-house technology will help us accelerate timelines across our programs.”

我们很高兴将他们的工作与我们在毛发再生领域的细胞和组织工程能力相结合，为脱发患者创造真正突破性的产品。Aderans技术和Stemson内部技术之间的协同作用将有助于我们加快整个项目的时间表。”

“Our pioneering work at the Aderans Research Institute to develop the first ever cell therapy solution for hair loss showed tremendous promise in clinical trials to treat early stage Androgenetic Alopecia in men and women,” declared Dr. Ken Washenik, M.D., Ph.D., Chief Medical Officer of Bosley Medical Group, The World’s Most Experienced Hair Restoration Experts®, and former Chief Executive Officer of Aderans Research Institute.

“我们在阿德兰研究所（Aderans Research Institute）开发有史以来第一种脱发细胞治疗方案的开创性工作，在治疗男性和女性早期雄激素性脱发的临床试验中显示出巨大的前景，”世界上最有经验的头发修复专家Bosley Medical Group®首席医疗官Ken Washenik博士宣布，和阿德兰研究所前首席执行官。

“We believe Stemson, with their advanced expertise in hair follicle cell and tissue engineering, is ideally positioned to successfully complete development and commercialization of this exciting hair regeneration solution.”

“我们相信，斯特姆森凭借其在毛囊细胞和组织工程方面的先进专业知识，能够成功完成这种令人兴奋的毛发再生解决方案的开发和商业化。”

“Aderans has been developing solutions for hair loss since our founding in 1968. Our agreement with Stemson positions our hair regeneration cell therapy technology to deliver advanced solutions to serve the global population,” added Yoshihiro Tsumura, Group CEO, Representative Director, and President of Aderans.

“自1968年成立以来，Aderans一直在开发脱发解决方案。我们与斯特姆森的协议将我们的毛发再生细胞治疗技术定位于提供先进的解决方案，以服务于全球人口，”集团首席执行官、代表董事兼Aderans总裁Yoshihiro Tsumura补充道。

“We look forward to working with the Stemson team to enable their development efforts and to support the commercialization through our global network of clinics serving hair loss patients.”

“我们期待着与斯特姆森团队合作，通过我们为脱发患者服务的全球诊所网络，推动他们的发展努力，并支持商业化。”

An estimated 80 million men, women, and children in the United States experience hair loss, which is often associated with emotional distress leading to reduced quality of life, anxiety, and depression. There are no existing therapeutic solutions capable of rejuvenating shrinking follicles, nor can they generate new hair follicles to replace lost hair.

据估计，美国有8000万男性、女性和儿童经历脱发，这通常与情绪困扰有关，导致生活质量下降，焦虑和抑郁。目前还没有能够使萎缩的毛囊恢复活力的治疗方案，也不能产生新的毛囊来替代掉的头发。

About Stemson Therapeutics

关于Stemson Therapeutics

Stemson Therapeutics is a pre-clinical stage cell therapy company founded in 2018 with a mission to cure hair loss by leveraging the regenerative power of Induced Pluripotent Stem Cells. Stemson uses iPSC to regenerate the critical cells required to grow hair and which are damaged or depleted in patients suffering from hair loss.

Stemson Therapeutics是一家成立于2018年的临床前阶段细胞治疗公司，其使命是通过利用诱导多能干细胞的再生能力来治疗脱发。斯特姆森使用iPSC再生生长头发所需的关键细胞，这些细胞在脱发患者中受损或耗尽。

The iPSC-derived cells are used to grow de novo hair follicles, offering a new supply of hair to treat people suffering from various forms of Alopecia. Today, there are no available treatments capable of growing new hair follicles. Stemson’s world class team of scientists, advisors and collaborators are passionate about delivering a scientifically based, clinically tested cure for hair loss to the millions of hair loss sufferers who seek help for their hair loss condition.

iPSC衍生的细胞用于从头生长毛囊，为治疗各种形式的脱发患者提供新的头发供应。今天，没有可用的治疗方法能够生长新的毛囊。斯特姆森的世界级科学家、顾问和合作者团队热衷于为数百万寻求脱发帮助的脱发患者提供一种基于科学、经过临床测试的脱发治疗方法。

About Aderans Company

关于Aderans公司

Aderans Company is a leading global provider of total hair solutions. Founded in 1968 and headquartered in Tokyo, Aderans has built a global presence across Asia, North America, and Europe to provide a wide range of hair solutions, including hair care products, advanced wig solutions, hair transplantation procedures, and non-surgical hair restoration and hair loss prevention services.

Aderans公司是全球领先的全发解决方案供应商。Aderans成立于1968年，总部位于东京，在亚洲、北美和欧洲建立了全球业务，提供多种头发解决方案，包括护发产品、高级假发解决方案、头发移植程序以及非手术头发修复和脱发预防服务。

Aderans owns well-known brands in North America such as Bosley and HAIRCLUB. Aderans invests in the research and development of advanced solutions for hair care and hair loss, which led them to pioneer innovations in cell therapy to treat hair loss through their Aderans Research Institute subsidiary, including development of a cell therapy product through Phase 2 clinical trials.

阿德兰在北美拥有博斯利（Bosley）和哈尔鲁布（Hairlub）等知名品牌。Aderans投资于头发护理和脱发高级解决方案的研究和开发，这使他们通过其Aderans研究所子公司率先在细胞疗法方面进行创新，以治疗脱发，包括通过第二阶段临床试验开发细胞疗法产品。